Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States

BACKGROUND: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised concern regarding the safety of dabigatran and rivaroxaban, but apixaban has not been evaluated despite current...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation
Hlavní autoři: Siontis, Konstantinos C., Zhang, Xiaosong, Eckard, Ashley, Bhave, Nicole, Schaubel, Douglas E., He, Kevin, Tilea, Anca, Stack, Austin G., Balkrishnan, Rajesh, Yao, Xiaoxi, Noseworthy, Peter A., Shah, Nilay D., Saran, Rajiv, Nallamothu, Brahmajee K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6202193/
https://ncbi.nlm.nih.gov/pubmed/29954737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.035418
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky